Hepatitis B vaccine recombinant - Crucell
Alternative Names: AgB; Biovac-B; Hepavax-Gene; Hepavax-Gene TF; SupervaxLatest Information Update: 15 May 2014
At a glance
- Originator Crucell; Dynavax Dusseldorf
- Developer Crucell; Dynavax Dusseldorf; Laboratorio Pablo Cassara
- Class DNA vaccines; Hepatitis B vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatitis B
Most Recent Events
- 01 Nov 2013 Crucell completes a phase III trial in Hepatitis B prevention in China (NCT01349283)
- 07 Jul 2011 Crucell initiates enrolment in a phase III trial in Hepatitis B pervention in China (NCT01349283)
- 22 Feb 2011 Crucell has been acquired by Johnson & Johnson